This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Melodiol Global Health Management

Management criteria checks 1/4

Melodiol Global Health's CEO is Will Lay, appointed in Jan 2022, has a tenure of 2.75 years. total yearly compensation is A$894.88K, comprised of 46% salary and 54% bonuses, including company stock and options. directly owns 0.006% of the company’s shares, worth A$70.81. The average tenure of the management team and the board of directors is 4.3 years and 2.8 years respectively.

Key information

Will Lay

Chief executive officer

AU$894.9k

Total compensation

CEO salary percentage	46.0%
CEO tenure	2.8yrs
CEO ownership	0.006%
Management average tenure	4.3yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Will Lay's remuneration changed compared to Melodiol Global Health's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	AU$895k	AU$412k	-AU$36m
Jun 30 2023	n/a	n/a	-AU$54m
Mar 31 2023	n/a	n/a	-AU$43m
Dec 31 2022	AU$408k	AU$389k	-AU$22m

Compensation vs Market: Will's total compensation ($USD588.46K) is above average for companies of similar size in the Australian market ($USD299.30K).

Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.

CEO

Will Lay

2.8yrs

Tenure

AU$894,875

Compensation

Mr. William Lay, also known as Will, B.Com (Hons.) is CEO & MD of Health House International Limited from 2024. He serves as Group Chief Executive Officer, Managing Director and Director at Melodiol Global...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Boaz Wachtel	Co-Founder & Non-Executive Chairman	8.9yrs	AU$80.00k	0.0015% A$ 17.2
William Lay	Group CEO	2.8yrs	AU$894.88k	0.0063% A$ 70.8
Christopher Grundy	Chief Financial Officer	6.9yrs	AU$628.01k	0.00014% A$ 1.6
Micheline MacKay	Executive Director	2.8yrs	AU$265.90k	0.00046% A$ 5.2
Gian Trepp	Commercial & Marketing Director	5.8yrs	no data	no data
Mitchel Fleming	Managing Director of Halucenex	no data	no data	no data
Brett Ayers	Managing Director of Impactive	no data	no data	no data
Winton Willesee	Joint Company Secretary	6yrs	no data	no data
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	2.9yrs	no data	no data

4.3yrs

Average Tenure

Experienced Management: ME1's management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Boaz Wachtel	Co-Founder & Non-Executive Chairman	8.9yrs	AU$80.00k	0.0015% A$ 17.2
William Lay	Group CEO	2.8yrs	AU$894.88k	0.0063% A$ 70.8
Micheline MacKay	Executive Director	2.8yrs	AU$265.90k	0.00046% A$ 5.2
Brian Walker	Strategic Consultant & Chair of Scientific Advisory Committee	2.9yrs	no data	no data
Walter Von Wartburg	Member of Scientific Advisory Board	5.8yrs	no data	no data
Bruce Linton	Independent Non-Executive Director	2.8yrs	AU$82.72k	0.0019% A$ 22.0
Isaac Kobrin	Member of Scientific Advisory Board	no data	no data	no data
Felix Gutzwiller	Member of Scientific Advisory Board	7.6yrs	no data	no data
Peter Hatfull	Non-Executive Director	1.9yrs	AU$83.26k	no data
Ben Quirin	Non-Executive Director	2yrs	AU$82.80k	no data

2.8yrs

Average Tenure

73.5yo

Average Age

Experienced Board: ME1's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

This company listing is no longer active

Melodiol Global Health Management

Management criteria checks 1/4

Key information

Recent management updates

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Less than half of directors are independent

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

New major risk - Negative shareholders equity

Full year 2023 earnings released: AU$0.019 loss per share (vs AU$0.45 loss in FY 2022)

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Less than half of directors are independent

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

First half 2022 earnings released: AU$0.006 loss per share (vs AU$0.018 loss in 1H 2021)

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Less than half of directors are independent

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Co-Founder & Non-Executive Chairman recently sold AU$4.5m worth of stock

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Full year 2020 earnings released: AU$0.083 loss per share (vs AU$0.10 loss in FY 2019)

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

Creso Pharma Limited has announced a Derivatives Offering in the amount of AUD 9.523042 million.

Creso Pharma Limited Secures New Purchase Order for its Leading Range of Animal Health Products Anibidiol

Creso Pharma Limited Secures First Purchase Order for Animal Health Products in LATAM

Creso Pharma Limited Announces TGA Decision to Reschedule CBD

New 90-day high: AU$0.24

Creso Pharma Limited Receives New Purchase Orders for Anibidiol® Products

Creso Pharma Limited Receives Second Purchase Order from Pharma Dynamics, South Africa

Creso Pharma Limited announced that it expects to receive AUD 8.992531 million in funding

First half earnings released

Creso Pharma Limited Announces CEO, Miri Halperin Wernli to Take Role of Technology, Innovation and Distribution Head

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age